282 related articles for article (PubMed ID: 22781599)
21. An amino acid polymorphism in von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13.
Bowen DJ; Collins PW
Blood; 2004 Feb; 103(3):941-7. PubMed ID: 14525793
[TBL] [Abstract][Full Text] [Related]
22. Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease.
Tjernberg P; Vos HL; Spaargaren-van Riel CC; Luken BM; Voorberg J; Bertina RM; Eikenboom JC
Thromb Haemost; 2006 Dec; 96(6):717-24. PubMed ID: 17139364
[TBL] [Abstract][Full Text] [Related]
23. Antibody-based prevention of von Willebrand factor degradation mediated by circulatory assist devices.
Rauch A; Legendre P; Christophe OD; Goudemand J; van Belle E; Vincentelli A; Denis CV; Susen S; Lenting PJ
Thromb Haemost; 2014 Nov; 112(5):1014-23. PubMed ID: 25030452
[TBL] [Abstract][Full Text] [Related]
24. von Willebrand disease type 2A phenotypes IIC, IID and IIE: A day in the life of shear-stressed mutant von Willebrand factor.
Brehm MA; Huck V; Aponte-Santamaría C; Obser T; Grässle S; Oyen F; Budde U; Schneppenheim S; Baldauf C; Gräter F; Schneider SW; Schneppenheim R
Thromb Haemost; 2014 Jul; 112(1):96-108. PubMed ID: 24598842
[TBL] [Abstract][Full Text] [Related]
25. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
Millar CM; Riddell AF; Brown SA; Starke R; Mackie I; Bowen DJ; Jenkins PV; van Mourik JA
Thromb Haemost; 2008 May; 99(5):916-24. PubMed ID: 18449422
[TBL] [Abstract][Full Text] [Related]
26. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
27. The WXXW motif in the TSR1 of ADAMTS13 is important for its secretion and proteolytic activity.
Ling J; Su J; Ma Z; Ruan C
Thromb Res; 2013 Jun; 131(6):529-34. PubMed ID: 23683325
[TBL] [Abstract][Full Text] [Related]
28. Light chain of factor VIII is sufficient for accelerating cleavage of von Willebrand factor by ADAMTS13 metalloprotease.
Cao W; Sabatino DE; Altynova E; Lange AM; Casina VC; Camire RM; Zheng XL
J Biol Chem; 2012 Sep; 287(39):32459-66. PubMed ID: 22854959
[TBL] [Abstract][Full Text] [Related]
29. Classification and characterization of hereditary types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
Clin Appl Thromb Hemost; 2006 Oct; 12(4):397-420. PubMed ID: 17000885
[TBL] [Abstract][Full Text] [Related]
30. C1584 in von Willebrand factor is necessary for enhanced proteolysis by ADAMTS13 in vitro.
Keeney S; Grundy P; Collins PW; Bowen DJ
Haemophilia; 2007 Jul; 13(4):405-8. PubMed ID: 17610557
[TBL] [Abstract][Full Text] [Related]
31. Insights into von Willebrand factor proteolysis: clinical implications.
Bowen DJ; Collins PW
Br J Haematol; 2006 Jun; 133(5):457-67. PubMed ID: 16681634
[TBL] [Abstract][Full Text] [Related]
32. Molecular characterization of four ADAMTS13 mutations responsible for congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).
Hommais A; Rayes J; Houllier A; Obert B; Legendre P; Veyradier A; Girma JP; Ribba AS
Thromb Haemost; 2007 Sep; 98(3):593-9. PubMed ID: 17849048
[TBL] [Abstract][Full Text] [Related]
33. Compromised shear-dependent cleavage of type 2N von Willebrand factor variants by ADAMTS13 in the presence of factor VIII.
Skipwith CG; Haberichter SL; Gehrand A; Zheng XL
Thromb Haemost; 2013 Jul; 110(1):202-4. PubMed ID: 23636243
[No Abstract] [Full Text] [Related]
34. Interactions of von Willebrand factor and ADAMTS13 in von Willebrand disease and thrombotic thrombocytopenic purpura.
Budde U; Schneppenheim R
Hamostaseologie; 2014; 34(3):215-25. PubMed ID: 25010251
[TBL] [Abstract][Full Text] [Related]
35. A new mutation, Ala1500-->Glu, responsible for type 2A von Willebrand disease.
Wang Y; Zhang J; Zhang W; Wan H; Ruan C
Int J Hematol; 2000 Dec; 72(4):512-6. PubMed ID: 11197223
[TBL] [Abstract][Full Text] [Related]
36. A conformation-sensitive monoclonal antibody against the A2 domain of von Willebrand factor reduces its proteolysis by ADAMTS13.
Zhang J; Ma Z; Dong N; Liu F; Su J; Zhao Y; Shen F; Wang A; Ruan C
PLoS One; 2011; 6(7):e22157. PubMed ID: 21779388
[TBL] [Abstract][Full Text] [Related]
37. Mutation G1629E Increases von Willebrand Factor Cleavage via a Cooperative Destabilization Mechanism.
Aponte-Santamaría C; Lippok S; Mittag JJ; Obser T; Schneppenheim R; Baldauf C; Gräter F; Budde U; Rädler JO
Biophys J; 2017 Jan; 112(1):57-65. PubMed ID: 28076816
[TBL] [Abstract][Full Text] [Related]
38. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B.
Rayes J; Hollestelle MJ; Legendre P; Marx I; de Groot PG; Christophe OD; Lenting PJ; Denis CV
Blood; 2010 Jun; 115(23):4870-7. PubMed ID: 20200350
[TBL] [Abstract][Full Text] [Related]
39. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD.
Kizlik-Masson C; Peyron I; Gangnard S; Le Goff G; Lenoir SM; Damodaran S; Clavel M; Roullet S; Regnault V; Rauch A; Vincent F; Jeanpierre E; Dupont A; Ternisien C; Donnet T; Christophe OD; van Belle E; Denis CV; Casari C; Susen S; Lenting PJ
Blood; 2023 Mar; 141(12):1457-1468. PubMed ID: 36564031
[TBL] [Abstract][Full Text] [Related]
40. [Von Willebrand factor and ADAMTS13 balancing primary haemostasis].
Schneppenheim R; Budde U
Hamostaseologie; 2011 Nov; 31(4):275-80. PubMed ID: 21792464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
